Renalytix (LON:RENX) Shares Down 3.2% – What’s Next?

Renalytix Plc (LON:RENX)’s share price was down 3.2% during mid-day trading on Thursday . The company traded as low as GBX 7.20 ($0.09) and last traded at GBX 7.50 ($0.09). Approximately 194,880 shares changed hands during mid-day trading, a decline of 55% from the average daily volume of 433,320 shares. The stock had previously closed at GBX 7.75 ($0.10).

Renalytix Stock Performance

The firm has a market capitalization of £12.32 million, a PE ratio of -30.94 and a beta of 2.10. The company has a debt-to-equity ratio of 173.95, a current ratio of 0.53 and a quick ratio of 2.42. The company’s fifty day simple moving average is GBX 8.15 and its 200 day simple moving average is GBX 12.84.

Insider Buying and Selling

In other news, insider Christopher H. B. Mills sold 83,696 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of GBX 8 ($0.10), for a total value of £6,695.68 ($8,393.73). 35.74% of the stock is owned by insiders.

Renalytix Company Profile

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score.